Android app Apple app link

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

By Yahoo! Finance   |   1 month ago
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

Bristol Myers Squibb faces a $6.7 billion lawsuit for allegedly delaying drug approvals, cheating former Celgene shareholders. The lawsuit claims the delay cost shareholders an extra $9 per share in cash. UMB Bank, now confirmed as trustee, filed the lawsuit after a previous dismissal.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.